196 related articles for article (PubMed ID: 38505446)
1. A Pathology Experience of Posttransplant Lymphoproliferative Disorder From One Tertiary Hospital: Pathology Concepts and Diagnostic Approach.
Al-Maghrabi H; Hafiz B; Meliti A
Cureus; 2024 Feb; 16(2):e54407. PubMed ID: 38505446
[TBL] [Abstract][Full Text] [Related]
2. Multicenter study of pediatric Epstein-Barr virus-negative monomorphic post solid organ transplant lymphoproliferative disorders.
Afify ZAM; Taj MM; Orjuela-Grimm M; Srivatsa K; Miller TP; Edington HJ; Dalal M; Robles J; Ford JB; Ehrhardt MJ; Ureda TJ; Rubinstein JD; McCormack S; Rivers JM; Chisholm KM; Kavanaugh MK; Bukowinski AJ; Friehling ED; Ford MC; Reddy SN; Marks LJ; Smith CM; Mason CC
Cancer; 2023 Mar; 129(5):780-789. PubMed ID: 36571557
[TBL] [Abstract][Full Text] [Related]
3. [Post-transplant lymphoproliferative disorder: a clinicopathologic study of 15 cases].
Chen DB; Wang Y; Song QJ; Shen DH
Zhonghua Bing Li Xue Za Zhi; 2012 Sep; 41(9):607-12. PubMed ID: 23157829
[TBL] [Abstract][Full Text] [Related]
4. Analysis of Post-Transplant Lymphoproliferative Disorder (PTLD) Outcomes with Epstein-Barr Virus (EBV) Assessments-A Single Tertiary Referral Center Experience and Review of Literature.
Lau E; Moyers JT; Wang BC; Jeong ISD; Lee J; Liu L; Kim M; Villicana R; Kim B; Mitchell J; Kamal MO; Chen CS; Liu Y; Wang J; Chinnock R; Cao H
Cancers (Basel); 2021 Feb; 13(4):. PubMed ID: 33669937
[TBL] [Abstract][Full Text] [Related]
5. Response to rituximab-based therapy and risk factor analysis in Epstein Barr Virus-related lymphoproliferative disorder after hematopoietic stem cell transplant in children and adults: a study from the Infectious Diseases Working Party of the European Group for Blood and Marrow Transplantation.
Styczynski J; Gil L; Tridello G; Ljungman P; Donnelly JP; van der Velden W; Omar H; Martino R; Halkes C; Faraci M; Theunissen K; Kalwak K; Hubacek P; Sica S; Nozzoli C; Fagioli F; Matthes S; Diaz MA; Migliavacca M; Balduzzi A; Tomaszewska A; Camara Rde L; van Biezen A; Hoek J; Iacobelli S; Einsele H; Cesaro S;
Clin Infect Dis; 2013 Sep; 57(6):794-802. PubMed ID: 23771985
[TBL] [Abstract][Full Text] [Related]
6. Posttransplant lymphoproliferative disorder in a heart transplant recipient: a case report.
Sahu MK; Singh SP; Satsangi A; Gogia A; Hote MP; Seth S
Indian J Thorac Cardiovasc Surg; 2023 Sep; 39(5):535-538. PubMed ID: 37609612
[TBL] [Abstract][Full Text] [Related]
7. [Post-transplant lymphoproliferative disease in liver transplant recipients--Merkur University Hospital single center experience].
Filipec-Kanizaj T; Budimir J; Colić-Cvrlje V; Kardum-Skelin I; Sustercić D; Naumovski-Mihalić S; Mrzljak A; Kolonić SO; Sobocan N; Bradić T; Dolić ZM; Kocman B; Katicić M; Zidovec-Lepej S; Vince A
Acta Med Croatica; 2011 Sep; 65 Suppl 1():37-43. PubMed ID: 23126028
[TBL] [Abstract][Full Text] [Related]
8. CD30 expression and survival in posttransplant lymphoproliferative disorders.
Kinch A; Amini RM; Hollander P; Molin D; Sundström C; Enblad G
Acta Oncol; 2020 Jun; 59(6):673-680. PubMed ID: 32102582
[No Abstract] [Full Text] [Related]
9. Posttransplant Lymphoproliferative Disorder Following Kidney Transplantation: A Review.
Sprangers B; Riella LV; Dierickx D
Am J Kidney Dis; 2021 Aug; 78(2):272-281. PubMed ID: 33774079
[TBL] [Abstract][Full Text] [Related]
10. Posttransplant lymphoproliferative disease: treatment and outcome in renal transplant recipients.
Soler MJ; Puig JM; Mir M; Parrilla J; Pedro C; Salar A; Serrano S; Lloveras J
Transplant Proc; 2003 Aug; 35(5):1709-13. PubMed ID: 12962767
[TBL] [Abstract][Full Text] [Related]
11. Post-transplant lymphoproliferative disorders, Epstein-Barr virus infection, and disease in solid organ transplantation: Guidelines from the American Society of Transplantation Infectious Diseases Community of Practice.
Allen UD; Preiksaitis JK;
Clin Transplant; 2019 Sep; 33(9):e13652. PubMed ID: 31230381
[TBL] [Abstract][Full Text] [Related]
12. Post-transplantation lymphoproliferative disorder in heart and kidney transplant patients: a single-center experience.
Wasson S; Zafar MN; Best J; Reddy HK
J Cardiovasc Pharmacol Ther; 2006 Mar; 11(1):77-83. PubMed ID: 16703222
[TBL] [Abstract][Full Text] [Related]
13. Case Report: Non-negligible Epstein-Barr virus-associated posttransplant lymphoproliferative disorders in a lung transplant recipient.
Hu J; Yu YW; Han DS; Li XJ; Zhang YQ; Cai HL; Xiao YH; Zheng X
Front Immunol; 2023; 14():1244534. PubMed ID: 37781359
[TBL] [Abstract][Full Text] [Related]
14. Risk factors evaluation of post-transplant lymphoproliferative disorders after allogeneic haematopoietic stem cell transplantation with comparison between paediatric and adult.
Chen DB; Liu XY; Kong FZ; Jiang Q; Shen DH
J Clin Pathol; 2021 Nov; 74(11):697-703. PubMed ID: 34011618
[TBL] [Abstract][Full Text] [Related]
15. A population-based study of 135 lymphomas after solid organ transplantation: The role of Epstein-Barr virus, hepatitis C and diffuse large B-cell lymphoma subtype in clinical presentation and survival.
Kinch A; Baecklund E; Backlin C; Ekman T; Molin D; Tufveson G; Fernberg P; Sundström C; Pauksens K; Enblad G
Acta Oncol; 2014 May; 53(5):669-79. PubMed ID: 24164103
[TBL] [Abstract][Full Text] [Related]
16. [Clinical Analysis of Post-Transplant Lymphoproliferative Disorder after Hematopoietic Stem Cell Transplantation in Severe Aplastic Anemia Patients].
Yan HM; Zheng XL; Zhu L; Ding L; Han DM; Liu J; Xue M; Li S; Wang HX
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2022 Aug; 30(4):1224-1229. PubMed ID: 35981389
[TBL] [Abstract][Full Text] [Related]
17. Risk factors and clinical outcomes of Epstein-Barr virus DNAemia and post-transplant lymphoproliferative disorders after haploidentical and matched-sibling PBSCT in patients with hematologic malignancies.
Gao XN; Lin J; Wang LJ; Li F; Li HH; Wang SH; Huang WR; Gao CJ; Yu L; Liu DH
Ann Hematol; 2019 Sep; 98(9):2163-2177. PubMed ID: 31243569
[TBL] [Abstract][Full Text] [Related]
18. Posttransplant lymphoproliferative disorder after umbilical cord blood transplantation in children.
Gong JZ; Bayerl MG; Sandhaus LM; Sebastian S; Rehder CW; Routbort M; Lagoo AS; Szabolcs P; Chiu J; Comito M; Buckley PJ
Am J Surg Pathol; 2006 Mar; 30(3):328-36. PubMed ID: 16538052
[TBL] [Abstract][Full Text] [Related]
19. Humanized anti-CD20 monoclonal antibody (Rituximab) treatment for post-transplant lymphoproliferative disorder.
Ganne V; Siddiqi N; Kamaplath B; Chang CC; Cohen EP; Bresnahan BA; Hariharan S
Clin Transplant; 2003 Oct; 17(5):417-22. PubMed ID: 14703923
[TBL] [Abstract][Full Text] [Related]
20. Post-transplantation lymphoproliferative disorders: Current concepts and future therapeutic approaches.
Abbas F; El Kossi M; Shaheen IS; Sharma A; Halawa A
World J Transplant; 2020 Feb; 10(2):29-46. PubMed ID: 32226769
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
